Advanced Search

Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2000 December;12(4) > Minerva Biotecnologica 2000 December;12(4):305-8



A Journal on Biotechnology and Molecular Biology

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

Frequency: Quarterly

ISSN 1120-4826

Online ISSN 1827-160X


Minerva Biotecnologica 2000 December;12(4):305-8


Macrocapsules as a novel alternative for systemic in vivo delivery of virus vector

Saller R. M. 1, Stange J. 2, Mitzner S. 2, Von Rombs K. 3, Hutzler P. 4, Dautzenberg H. 5, Gunzburg W. H. 1, Salmons B. 3

1 Institute of Molecular Virology, GSF-Research Centre for Environmental and Health Research, Oberschleißheim;
2 Klinik für Innere Medizin, University of Rostock, Rostock;
3 Bavarian Nordic Research Institute, Martinsried;
4 Institute of Pathology, GSF-Research Centre for Environmental and Health Research, Oberschleißheim;
5 University of Potsdam, Teltow, Germany

Retroviral vectors (RV) are a promising tool to deliver genes to cells. They have been used in a number of gene therapy trials. However, due to their short half-life and low titres their use is mostly limited to an in vitro therapy. Therefore it would be desirable to administer the RV over a longer period rather than a giving it as a bolus. We tried to establish a “microfactory” in vivo, which should be able to produce and release RV continuously. The first step is the characterisation of the virus-producing capsule, which will be discussed here. The data presented show that virus producing cells not only tolerate the encapsulation process, but also survive for a period of at least six weeks and release RV from the capsule.

language: English


top of page